Summary of Significant Accounting Policies - Schedule of Percentage of Revenue and Accounts Receivables from Customers (Details) - Customer Concentration Risk	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024	Dec. 31, 2024
Revenue | Moderna Inc
Summary Of Significant Accounting Policies [Line Items]
Concentration risk percentage	19.00%	33.00%	25.00%	28.00%
Revenue | Regeneron Pharmaceuticals
Summary Of Significant Accounting Policies [Line Items]
Concentration risk percentage	19.00%
Revenue | Pfizer Inc.
Summary Of Significant Accounting Policies [Line Items]
Concentration risk percentage	11.00%
Revenue | Natera Inc.
Summary Of Significant Accounting Policies [Line Items]
Concentration risk percentage		20.00%	10.00%	31.00%
Revenue | VA MVP
Summary Of Significant Accounting Policies [Line Items]
Concentration risk percentage		17.00%	15.00%	11.00%
Accounts Receivable | Moderna Inc
Summary Of Significant Accounting Policies [Line Items]
Concentration risk percentage			11.00%
Accounts Receivable | Regeneron Pharmaceuticals
Summary Of Significant Accounting Policies [Line Items]
Concentration risk percentage			19.00%
Accounts Receivable | Pfizer Inc.
Summary Of Significant Accounting Policies [Line Items]
Concentration risk percentage			12.00%		25.00%
Accounts Receivable | Natera Inc.
Summary Of Significant Accounting Policies [Line Items]
Concentration risk percentage					13.00%
Accounts Receivable | Merck & Co., Inc.
Summary Of Significant Accounting Policies [Line Items]
Concentration risk percentage			18.00%		31.00%